Press Releases

August 8, 2019
Gossamer Bio Announces Second Quarter 2019 Financial Results
– Immuno-oncology candidate, GB1275, advances to clinic for selected solid tumor types – – Five active clinical trials across four clinical programs, with data readouts for all four programs expected in 2020 – – Company to host conference call today at 4:30 p.m.
Additional Formats
May 14, 2019
Gossamer Bio Announces First Quarter 2019 Financial Results
– Multiple trial initiations and data readouts expected in the next 12 months – – Company to host conference call today at 8:30 a.m. ET – SAN DIEGO --(BUSINESS WIRE)--May 14, 2019-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring,
Additional Formats
May 2, 2019
Gossamer Bio Secures Debt Facility for up to $150 Million
SAN DIEGO --(BUSINESS WIRE)--May 2, 2019-- Gossamer Bio, Inc. (Nasdaq:GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced it entered into a
Additional Formats
March 22, 2019
Gossamer Bio Announces 2018 Annual Financial Results
SAN DIEGO --(BUSINESS WIRE)--Mar. 22, 2019-- Gossamer Bio, Inc. (Nasdaq:GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced its financial
Additional Formats
February 22, 2019
Gossamer Bio Announces Participation in Upcoming Investor Conferences
SAN DIEGO --(BUSINESS WIRE)--Feb. 22, 2019-- Gossamer Bio, Inc.  (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that Sheila
Additional Formats
Displaying 1 - 10 of 14